



X-linked myxomatous valvular dystrophy in patient with a novel mutation in *FLNA* gene

Authors: Agnieszka Madej-Pilarczyk, Dorota Piekutowska-Abramczuk, Beata Kucińska, Mariusz Furmanek, Anna Gwiazda, Elżbieta Ciara, Krystyna H Chrzanowska, Bożena Werner

Article type: Clinical vignette

Received: November 22, 2022

Accepted: December 23, 2022

Early publication date: January 14, 2023

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

X-linked myxomatous valvular dystrophy in patient with a novel mutation in *FLNA* gene

Short title: Myxomatous valvular dystrophy due to *FLNA* mutation

Agnieszka Madej-Pilarczyk^{1*}, Dorota Piekutowska-Abramczuk^{1*}, Beata Kucińska², Mariusz Furmanek³, Anna Gwiazda³, Elżbieta Ciara¹, Krystyna H Chrzanowska¹, Bożena Werner²

¹Department of Medical Genetics, The Children's Memorial Health Institute, Warszawa, Poland

²Department of Pediatric Cardiology and General Pediatrics, Medical University of Warsaw, Warszawa, Poland

³Department of Pediatric Radiology, Medical University of Warsaw, Warszawa, Poland

*Both authors equally contributed to the study

Correspondence to:

Agnieszka Madej-Pilarczyk, MD, PhD,
Department of Medical Genetics,
The Children's Memorial Health Institute,
Dzieci Polskich 20, 04–736 Warszawa, Poland,
phone: +48 22 815 74 46,
e-mail: a.madej-pilarczyk@ipczd.pl

Molecular variants in *FLNA* are associated with wide spectrum of neurological, dysmorphic and skeletal phenotypes with X-linked trait of inheritance (recessive or dominant): periventricular heterotopia, multiple malformation syndromes, short bowel syndrome, terminal osseous dysplasia, but also X-linked recessive cardiac valvular dystrophy (CVDPX; OMIM#314400, ORPHA:555877). Until now there have been only few reports of CVDPX in the literature [1–5]. We report the case of a 14-years-old boy, who was presented in the outpatient genetic clinic due to multivalvular heart disease, generalized joint laxity, scoliosis, hyperelastic skin and dysmorphic features: ocular hypertelorism with prominent supraorbital ridges and ptosis, external rotation of 5th toe.

During routine follow-up at the age of 4-years heart systolic murmur and midsystolic click were noticed. Echocardiography revealed mitral and tricuspid valve prolapse with moderate regurgitation. Valve leaflets were thickened with myxomatous changes (Figure 1A–F). After 5 years follow-up mild aortic valve regurgitation with slight myxomatous changes of the leaflets was noted. Progression of tricuspid regurgitation, enlargement of right atrium (RA) and right ventricle (RV), slightly decreased contractility of the left ventricle (LV) with ejection fraction 53% (Simpson method) appeared after subsequent 4 years. There was no dilatation of any valvular annulus. Holter ECG monitoring did not show arrhythmia. Cardiac magnetic resonance (CMR) confirmed myxomatous multivalvular dystrophy, slightly decreased LV ejection fraction (53%), increased indexed RV volume and RA enlargement. No late gadolinium enhancement was detected.

Family history revealed that the proband's mother had prolapse of posterior mitral valve leaflet accompanied with mild late systolic regurgitation, mild aortic regurgitation, and normal ejection fraction. Her genetic testing is ongoing. No pathological findings on echocardiography in the proband's younger brother were found (Figure 1G).

Overall clinical presentation was consistent with a congenital connective tissue pathology with multivalvular heart involvement. Next generation sequencing showed a novel hemizygous substitution c.869-2A>G in intron 5 of *FLNA* gene, which was predicted to abolish the canonical splice site in intron 5, resulting in exon 6 skipping and leads to loss-of-function of filamin A, widely expressed actin-binding protein, being a central mechanotransduction element of the cytoskeleton, which plays a role in cell-cell contacts during the development of blood vessels, heart and brain. Known mutations in *FLNA* gene, which were described in patients with CVDPX, included missense changes all involve highly conserved residues within the first, fourth, and fifth repeat consensus sequences of filamin A and the deletion which leads to synthesis of the truncated protein lacking repeats 5 through 7. The substitution c.869-2A>G is located in intron 5, therefore probably disrupts the protein within the first repeat consensus sequence (Figure 1H). The clinical course of the disease together with the genetic test result strongly justify the diagnosis of CVDPX in this patient.

Our report extends genotype spectrum of *FLNA*-related CVDPX. Diagnostic approach in multivalvular heart disease should include ultra-rare disorders and their causative genes, which

encode proteins involved in intracellular interactions of major importance for the structure and function of the heart.

Article information

Conflict of interest: None declared.

Funding: This work was supported by Children's Memorial Health Institute grant S182/2019 to AMP.

Open access: This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. For commercial use, please contact the journal office at kardiologiapolska@ptkardio.pl.

REFERENCES

1. Kyndt F, Gueffet JP, Probst V, et al. Mutations in the gene encoding filamin A as a cause for familial cardiac valvular dystrophy. *Circulation*. 2007; 115(1): 40–49, doi: [10.1161/CIRCULATIONAHA.106.622621](https://doi.org/10.1161/CIRCULATIONAHA.106.622621), indexed in Pubmed: [17190868](https://pubmed.ncbi.nlm.nih.gov/17190868/).
2. Tessler I, Reshef N, Shpitzen S, et al. Mitral valve prolapse: From new mechanisms to diagnostic challenges. *Kardiol Pol*. 2022; 80(9): 891–896, doi: [10.33963/KP.a2022.0147](https://doi.org/10.33963/KP.a2022.0147), indexed in Pubmed: [35724336](https://pubmed.ncbi.nlm.nih.gov/35724336/).
3. Lardeux A, Kyndt F, Lecoite S, et al. Filamin-a-related myxomatous mitral valve dystrophy: genetic, echocardiographic and functional aspects. *J Cardiovasc Transl Res*. 2011; 4(6): 748–756, doi: [10.1007/s12265-011-9308-9](https://doi.org/10.1007/s12265-011-9308-9), indexed in Pubmed: [21773876](https://pubmed.ncbi.nlm.nih.gov/21773876/).
4. Aalberts JJJ, van Tintelen JP, Oomen T, et al. Screening of TGFBR1, TGFBR2, and FLNA in familial mitral valve prolapse. *Am J Med Genet A*. 2014; 164A(1): 113–119, doi: [10.1002/ajmg.a.36211](https://doi.org/10.1002/ajmg.a.36211), indexed in Pubmed: [24243761](https://pubmed.ncbi.nlm.nih.gov/24243761/).
5. Ma PH, Sachdeva R, Wilson EC, et al. Longitudinal echocardiographic evaluation of an unusual presentation of x-linked myxomatous valvular dystrophy caused by filamin a mutation. *Semin Cardiothorac Vasc Anesth*. 2016; 20(3): 240–245, doi: [10.1177/1089253216640088](https://doi.org/10.1177/1089253216640088), indexed in Pubmed: [27004951](https://pubmed.ncbi.nlm.nih.gov/27004951/).




Figure 1. **A.** ECHO-2D. Apical 4-chamber view, tricuspid and mitral valve prolapse with tricuspid and mitral regurgitations. **B.** ECHO-2D. Parasternal long axis view, mitral valve prolapse with myxomatous changes (arrows). **C.** ECHO-2D. Parasternal short axis mitral view, thickened myxomatous leaflets. **D.** CMR. 4-chamber, thickened leaflets of mitral valve (green arrow). **E.** CMR. 3-chambers, thickened leaflets of mitral valve (green arrow). **F.** CMR. thickened leaflets of aortic valve (green arrow). **G.** Pedigree of the family. Filled symbol —affected individual, symbol with dot — presumptive female carrier. **H.** Disease causing molecular variants in *FLNA* gene identified in the patients with cardiac valvular dysplasia according to RefSeq NM_001110556.2 (HGMD Professional 2022.3); exons — dark grey

Abbreviations: Ao, aorta; CMR, cardiac magnetic resonance; ECHO-2D, two dimensional echocardiography; MR, mitral regurgitation; LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle; TR, tricuspid regurgitation;